LONDON – The World Health Organization held off declaring the novel coronavirus infection that has emerged in Wuhan, China, an international public health emergency, despite the fact that the number of confirmed cases tripled in the past week and the infection has spread to several other countries, including the U.S.
In response to the emergence of a new coronavirus seen recently in China, and now America, Novavax Inc. has initiated development of a vaccine candidate, the company told BioWorld. Company shares (NASDAQ:NVAX) climbed more than 71% Jan. 21, ending the day at $9.82.
Researchers at the Christian Albrechts University of Kiel and the MRC London Institute of Medical Science have developed a way to screen four-way interactions between genetically simple hosts, their microbiome, nutrients and drugs.
LONDON – Themis Bioscience GmbH has landed an exclusive licensing deal with Merck & Co. Inc., which simultaneously validates its measles virus-based vaccines platform and provides the means to extend the technology to new indications.
LONDON – Themis Bioscience GmbH has announced positive phase II results for its vaccine against Chikungunya virus, as it moves to complete an IPO later this week to raise up to €55 million (US$62.6 million) to fund the launch of a pivotal phase III trial.